Insider · CIK 0001242215
Joseph C Papa
Files at EBS (Emergent BioSolutions Inc.), MIST (Milestone Pharmaceuticals Inc.), CADL (Candel Therapeutics, Inc.). First filing May 15, 2025, latest May 15, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EBS: Emergent BioSolutions Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | EBSbuy Emergent BioSolutions Inc. | $350k 60,000 shares | +21% | +38% from low-51% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,325 | $8.68 | $11k | 1,325 | 10 d ago |
| Jul 11, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Common Shares | +100,000 | - | - | 100,000 | Jul 15, 2025 |
| Jul 11, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Series A Common Warrants (right to buy)derivative | +100,000 | - | - | 100,000 | Jul 15, 2025 |
| Jul 11, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Series B Common Warrants (right to buy)derivative | +100,000 | - | - | 100,000 | Jul 15, 2025 |
| Jun 25, 2025 | CADL Candel Therapeutics, Inc. | AGrant or award Common Stockindirect: By Joseph C. Papa Revocable Living Trust | +64,239 | $4.67 | $300k | 64,239 | Jun 26, 2025 |
| Jun 17, 2025 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,240 | $0.00 | $0 | 14,240 | Jun 18, 2025 |
| Jun 10, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 12, 2025 |
| May 13, 2025 | EBS Emergent BioSolutions Inc. | POpen-market purchase Common Stock | +60,000 | $5.83 | $350k | 342,500 | May 15, 2025 |
| Mar 12, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Options (Right to Buy)derivative | +250,000 | $0.00 | $0 | 1,282,500 | Mar 12, 2025 |
| Mar 12, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Options (Right to Buy)derivative | +250,000 | $0.00 | $0 | 1,532,500 | Mar 12, 2025 |
| Mar 6, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock | +282,500 | $0.00 | $0 | 282,500 | Mar 10, 2025 |
| Mar 6, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Options (Right to Buy)derivative | +282,500 | $0.00 | $0 | 1,032,500 | Mar 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.